A group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
The acquisition is carried out by a selected group of non-institutional chilean investors.
Founded in 1968, Farmacias Ahumada operates as one of the three main pharmaceutical chains in Chile, with almost 300 drugstores. It offers a range of products and services, such as drugs, natural products, nutritional supplements and beauty items and personal care products. The company is based in Santiago.
Walgreens Boots Alliance is an American public multinational holding headquartered in Illinois. It is an integrated healthcare, pharmacy and retail leader, which owns the pharmacy chains Walgreens in the US and Boots in the UK and internationally, as well as the Benavides brand in Mexico.
Oaklins’ team in Chile advised a group of Chilean investors on the acquisition of Farmacias Ahumada.
Talk to the deal team
Related deals
Armira has signed an agreement to acquire a majority stake in Viabus
Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more